First precision protocol against children's cancer - Biotech. Born in Italy and based on the genome, neuroblastoma in the sights.
The first study, conducted on 18 children, was recently published in the Journal of Translational Medicine. Two-thirds of these cases were classified as'very high priority', opening up the possibility of benefiting from drugs already approved or new therapeutic agents in development. The genetic identikit of the tumor is obtained and on this basis the therapies that have the greatest probability of success are then identified.